Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

• Research
• Open Access
• 
  

• Toshihiro Masuda, 
• Eiji Nakatani, 
• Toshihiro Shirai, 
• Taisuke Akamatsu, 
• Kanami Tamura, 
• Shingo Takahashi, 
• Yuko Tanaka, 
• Hirofumi Watanabe, 
• Yoshinari Endo, 
• Takahito Suzuki, 
• Mika Saigusa, 
• Akito Yamamoto, 
• Satoru Morita, 
• Yoko Sato & 
• Kazuhiro Asada 

BMC Pulmonary Medicine volume 21, Article number: 123 (2021) 

Abstract

Background

The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial.

Methods

To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case–control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department.

Results

There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12).

Conclusion

This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.

Download PDF